A self-powered bidirectional partition microfluidic chip with embedded microwells for highly sensitive detection of EGFR mutations in plasma of non-small cell lung cancer patients

被引:18
|
作者
Wu, Wenshuai [1 ,2 ]
Wu, Fengtian [3 ]
Zhang, Shan [1 ,2 ]
Ding, Xiong [1 ,2 ]
Zhang, Tao [1 ]
Yang, Ying [3 ]
Mu, Ying [1 ]
机构
[1] Zhejiang Univ, Res Ctr Analyt Instrumentat, Inst Cyber Syst & Control, State Key Lab Ind Control Technol, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med,Collaborat Innovat Ctr Diag & Treatment, Natl Clin Res Ctr Infect Dis,State Key Lab Diag &, Hangzhou 310058, Peoples R China
基金
国家重点研发计划;
关键词
Digital PCR chip; Bidirectional partition network; Embedded microwell; Self-powered; CtDNA analysis; Tumor dynamics monitoring; GROWTH-FACTOR RECEPTOR; CIRCULATING TUMOR DNA; DROPLET DIGITAL PCR; KRAS MUTATIONS; ABSOLUTE QUANTIFICATION; PDMS; PLATFORM;
D O I
10.1016/j.talanta.2020.121426
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Circulating tumor DNA (ctDNA) is a promising biomarker for tumor genotyping and therapy monitoring. Herein, we developed a digital PCR chip with embedded microwell and bidirectional partition network for highly sensitive ctDNA analysis. The embedded microwell contributes to increasing microreaction density (up to 7000 microwells/cm(2)) and reducing evaporation during amplification. The bidirectional partition network can achieve fast and random distribution of targets, ensuring the precise quantification of nucleic acid. We used plasmids, artificial samples and 32 clinical blood samples from non-small cell lung cancer patients to test the performance of this platform. The results demonstrated that our chip has not only comparable quantification performance to commercial counterpart but also the ability to detect EGFR mutations with as low as 0.01% mutation rate and 20 alter molecules in 27 ng genomic DNA. The identification of EGFR mutations in plasma using developed chip exhibited 85.71% sensitivity and 94.44% specificity for L858R mutation and 100% sensitivity and 86.96% specificity for T790 M mutation. Moreover, the monitoring of mutant allele in plasma was accomplished in this work. In conclusion, the developed chip has a potential in lung tumor genotyping and therapy monitoring for precision medicine, even other tumors.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer
    Sow, Mohamed Lemine
    El Yacoubi, Hind
    Moukafih, Badreddine
    Balde, Salif
    Akimana, Gloria
    Najem, Salma
    El Khoyaali, Siham
    Abahssain, Halima
    Chaibi, Aicha
    Khan, Shah Zeb
    Trapani, Dario
    Benzekri, Asmae
    Ghaouti, Merieme
    Gamra, Lamia
    Mestari, Amina
    Kettani, Fouad
    Rahali, Younes
    Mrabti, Hind
    Elghissassi, Ibrahim
    Errihani, Hassan
    TUMORI JOURNAL, 2021, 107 (04): : 335 - 340
  • [22] Uncommon EGFR mutations in advanced non-small cell lung cancer
    O'Kane, Grainne M.
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Liu, Geoffrey
    Pisters, Katherine -M.
    Kamel-Reid, Suzanne
    Tsao, Ming S.
    Shepherd, Frances A.
    LUNG CANCER, 2017, 109 : 137 - 144
  • [23] EGFR mutations in non-small cell lung cancer - Clinical implications
    Charpidou, Andriani
    Blatza, Despoina
    Anagnostou, Elsa
    Syrigos, Konstantinos N.
    IN VIVO, 2008, 22 (04): : 529 - 536
  • [24] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Leah Wells
    Angel Qin
    Current Treatment Options in Oncology, 2023, 24 : 1802 - 1814
  • [25] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Wells, Leah
    Qin, Angel
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1978 - 1993
  • [26] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Bruce E. Johnson
    David Jackman
    Pasi A. Jänne
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 5 - 9
  • [27] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (Suppl 1) : S5 - S9
  • [28] Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
    Britta Weber
    Peter Meldgaard
    Henrik Hager
    Lin Wu
    Wen Wei
    Julie Tsai
    Azza Khalil
    Ebba Nexo
    Boe S Sorensen
    BMC Cancer, 14
  • [29] Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
    Weber, Britta
    Meldgaard, Peter
    Hager, Henrik
    Wu, Lin
    Wei, Wen
    Tsai, Julie
    Khalil, Azza
    Nexo, Ebba
    Sorensen, Boe S.
    BMC CANCER, 2014, 14
  • [30] The detection of EGFR mutations in patients with non-small cell lung cancer in selected molecular diagnostics centers in Poland
    Krawczyk, Pawel
    Ramlau, Rodryg
    Powrozek, Tomasz
    Wojas-Krawczyk, Kamila
    Sura, Sylwia
    Jarosz, Bozena
    Walczyna, Beata
    Pankowski, Juliusz
    Szumilo, Justyna
    Dyszkiewicz, Wojciech
    Wozniak, Aldona
    Milanowski, Janusz
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 9 (04) : 431 - 438